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   ABSTRACT 
  Background      The value of clinical items deﬁ  ning 
inﬂ  ammatory back pain to identify patients with axial 
spondyloarthritis (SpA) in primary care is unclear.   
  Objective      To identify predictive clinical parameters for a 
diagnosis of axial SpA in patients with chronic back pain 
presenting in primary care.   
  Methods      Consecutive patients aged <45 years 
(n=950) with back pain for >2 months who 
presented to orthopaedic surgeons (n=143) were 
randomised based on four key questions for referral to 
rheumatologists (n=36) for diagnosis.   
  Results      The rheumatologists saw 322 representative 
patients (mean age 36 years, 50% female, median 
duration of back pain 30 months). 113 patients (35%) 
were diagnosed as axial SpA (62% HLA B27+), 47 
(15%) as ankylosing spondylitis (AS) and 66 (21%) 
as axial non-radiographic SpA (nrSpA). Age at onset 
≤35 years, improvement by exercise, improvement 
with non-steroidal anti-inﬂ  ammatory drugs, waking up 
in the second half of the night and alternating buttock 
pain were identiﬁ  ed as most relevant for diagnosing 
axial SpA by multiple regression analysis. Differences 
between AS and nrSpA were detected. No single 
item was predictive, but ≥3 items proved useful for 
good sensitivity and speciﬁ  city by receiver operating 
characteristic modelling.   
  Conclusion      This study shows that a preselection in 
primary care of patients with back pain based on a 
combination of clinical items is useful to facilitate the 
diagnosis  of  axial  SpA.      
  The term spondyloarthritis (SpA) covers a hetero-
geneous group of rheumatic diseases characterised 
by common clinical symptoms such as inﬂ  amma-
tory back pain (IBP) which is considered the leading 
symptom in patients with the condition.    1    Patients 
with SpA have been divided into two subgroups 
according to the predominant symptoms,    2        3    which 
can either be localised in the spine (axial SpA) or in 
the peripheral joints (peripheral SpA). Ankylosing 
spondylitis (AS), the prototype of axial SpA, is 
characterised by spinal stiffness.    1    The other com-
mon differentiations used to diagnose or classify 
patients with SpA are the presence of a disease-
deﬁ   ning feature such as psoriasis, inﬂ  ammatory 
bowel disease (IBD, Crohn’s disease or ulcerative 
colitis) or the history of a triggering infection in the 
enteral or urogenital tract (reactive arthritis). In the 
absence of these features, the term ‘undifferentiated 
SpA’ (uSpA) has been used while, for patients with 
IBP but without structural changes in the sacroiliac 
joints and the spine, the term ‘non-radiographic 
axial SpA’ (nrSpA) is used.    4    Not all patients with 
SpA will develop AS.    5        6    
  A signiﬁ  cant delay in diagnosing AS has been 
reported.    7    The new Assessment of SpondyloArthritis 
international Society (ASAS) classiﬁ  cation criteria    2    
    3    are a step forward in making an earlier diagnosis 
of patients with axial SpA, but it is unclear whether 
they work in primary care. Possible screening tools 
for axial SpA including IBP and HLA B27 were pro-
posed some years ago in patients with chronic back 
pain.    8    Some of the proposed items were tested in a 
referral    9    and a cohort study.    10    
  The major clinical item in SpA is IBP, ﬁ  rst deﬁ  ned 
in 1977.    11        12    IBP has long been a central part of the 
classiﬁ   cation criteria for AS    13    and SpA.    14    Novel 
deﬁ  nitions for IBP have recently been proposed.    11    
    15        16    In a population-based study, many false posi-
tive answers to questions on IBP were found in 
controls.    17    
  Chronic back pain is a common symptom of 
patients presenting to GPs and orthopaedic sur-
geons.    18    The general perception and approach to 
the diagnosis and management of AS has been 
reported to be in part inconsistent in primary 
care.    19    There is limited knowledge on the preva-
lence of IBP due to SpA in primary care, but one 
study reported a prevalence of 5% among patients 
with chronic back pain,    20    a percentage similar to 
that recently reported by chiropractitioners.    21    Of 
course, the prevalence of SpA in patients present-
ing to rheumatologists is likely to be signiﬁ  cantly 
higher, reﬂ  ecting the different pretest probability 
of SpA.    22    
  The aim of this study was to test different IBP-
related clinical items in primary care. 
  METHODS 
  This study was designed as a prospective case 
ascertainment trial that included a stratiﬁ  cation 
step based on prespeciﬁ  ed recognition criteria lead-
ing to a randomised selection for referral to a rheu-
matologist. A total of 143 orthopaedic surgeons in 
private practice and 36 rheumatologists took part in 
the study. The time frame was April 2007 to June 
2009 for screening and May 2007 to May 2009 for 
validation. 
  The study plan was to identify 1000 patients in 
primary care with chronic back pain for >2 months 
and <10 years in whom back pain ﬁ  rst occurred 
between the ages of 16 and 45 years, and to refer 
to rheumatologists about 400 patients after stratiﬁ  -
cation and randomised selection performed by an 
independent institute based on four prespeciﬁ  ed 
recognition criteria: (1) morning stiffness >30 min; 
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  RESULTS 
    Description of patient populations studied 
  A total of 1074 patients were included, of whom 950 could be 
analysed; 670 were referred to a rheumatologist of whom 334 
attended, and 322 patients with complete data were available 
for analysis. The rheumatological examinations were performed 
a median of 20 days after the initial visit to primary care. 
  The relative frequency of the prespeciﬁ  ed recognition criteria 
in the different subsets is shown in   table 1   and the relative fre-
quency of positive answers in   table 2  . Overall, there was no dif-
ference between the demographic characteristics of the patients 
referred to the rheumatologist and the total study population.     
  The characteristics of the 322 patients with complete data 
were: mean age 36±7.9 years, 49.4% male, mean height of men 
181±7 cm, mean height of women 167±6 cm, mean weight of 
men 85.6±14.5 kg and mean weight of women 67±16.7 kg. The 
age at symptom onset was 32.2±7.4 years and the mean dura-
tion of complaints was 44.2±38.1 months. 
  The distribution within the age groups was 13 patients (4%) 
aged <20 years, 67 (21%) aged 21–30 years, 134 (42%) aged 
31–40 years, 104 (32%) aged 41–50 years and 4 (1%) aged >50 
years. Fifty-eight patients (18%) reported having had back pain 
for <6 months, 43 (13%) for 6–12 months, 51 (16%) for 12–24 
months, 84 (26%) for 24–60 months and 86 (27%) for >60 
months. Twenty-two (7%) reported age at onset of <20 years, 
49 (15%) at age 21–25 years, 49 (15%) at age 26–30 years, 85 
(26%) at age 31–35 years, 69 (21%) at age 36–40 years and 48 
(15%) at age 41–45 years.   
    Patient diagnoses, demographics and clinical manifestations 
  As shown in   table 3  , 113 patients were diagnosed with SpA (66 
with nrSpA and 47 with deﬁ  nite AS) and 209 patients were diag-
nosed as non-SpA. The majority of the latter group had non-
speciﬁ  c lower back pain or degenerative disc disease.   
  The mean age of the patients with SpA was 36 years. The rel-
ative distribution of the different age groups was similar among 
the 113 patients with SpA and the 209 non-SpA patients (9 (8%) 
vs 13 (6.2%) <20 years, 44 (38.9%) vs 54 (25.9%) 20–30 years, 
53 (45.1%) vs 103 (49.3%) 30–40 years and 9 (8%) vs 39 (18.7%) 
>40 years). 
  The age distribution between patients with AS and nrSpA 
was 26 (55%) versus 27 (41%) in those aged <20–30 years and 
21 (45%) versus 39 (59%) in those aged <30–45 years. 
  Extraspinal manifestations were reported in 23.5%, enthesitis/
heel pain in 11%, arthritis/joint swelling without trauma in 7% 
and psoriasis in 6% of patients with SpA. A family history of AS 
and SpA was reported in 4% and 2% of patients, respectively.   
  HLA  B27  results 
  HLA B27 was positive in 35/46 patients with AS (76.1%), in 
31/60 with axial uSpA (51.7%), in 66/106 patients with axial 
(2) improvement by movement not by rest; (3) waking up in the 
second half of the night because of back pain; and (4) improve-
ment with non-steroidal anti-inﬂ   ammatory drugs (NSAIDs) 
within 48 h. The answers to these questions, which were col-
lected at the initial visit by the orthopaedic surgeons and trans-
mitted for patient randomisation at the independent institute, 
were the basis for stratiﬁ  cation into 16 cohorts. The rheuma-
tologists, who were aware of the current classiﬁ  cation criteria, 
made the ﬁ  nal diagnosis. These data allowed validation of clini-
cal questions and screening parameters and an analysis of the 
relative value of combinations of parameters. 
  Secondary criteria analysed were alternating buttock pain, a 
positive family history of SpA and extraspinal manifestations 
(presence or history of arthritis, enthesitis, psoriasis, IBD and 
HLA-B27). 
  Statistical  analysis 
  The information was centrally collected at the Institut for 
Statistics of Dr Schnitker in Bielefeld, Germany where blinded 
decisions were made randomly as to which patients to refer to 
rheumatologists. Clinical information was sent to the institute 
where the statistical analyses were performed. 
  Descriptive statistics were made by standard methods. Logistic 
regression analysis with backward elimination was performed 
with several parameters as independent variables. The depen-
dent variable was the diagnosis of axial SpA, AS and nrSpA by 
the rheumatologist. In addition, receiver operating characteristic 
(ROC) curves were calculated. HLA B27 was excluded from the 
analyses.     
  Table  1         Relative frequency of recognition criteria C1–C4 in the cohorts 
referred to the rheumatologist (n=670)   
 Cohort   C1   C2   C3   C4   Frequency 
1 – – – – 21 (3.1%)
2 ■ – – – 17 (2.5%)
3– ■ – – 50 (7.5%)
4– – ■ – 26 (3.9%)
5– – – ■ 46 (6.9%)
6 ■■– – 27 (4.0%)
7 ■ – ■ – 8 (1.2%)
8 ■ ––■ 19 (2.8%)
9– ■■– 100 (14.9%)
10 – ■ – ■ 93 (13.9%)
11 – – ■■ 34 (5.1%)
12 ■■■– 39 (5.8%)
13 ■■– ■ 29 (4.3%)
14 ■ – ■■ 14 (2.1%)
15 – ■■■ 94 (14.0%)
16 ■ ■ ■ ■ 53 (7.9%)
      Prespeciﬁ  ed recognition criteria: C1, morning stiffness >30 min; C2, improvement by 
movement not by rest; C3, waking up in the second half of the night because of back 
pain; C4, improvement with non-steroidal anti-inﬂ  ammatory drugs within 48 h.
The ﬁ  lled boxes indicate that these items were present, the bars indicate absence.     
  Table  2         Relative frequency of positive answers for the entry criteria   
 Criteria 
 Cohort 
 Screening  
(n=950) 
 Referral  
(n=670) 
 Validation  
(n=334) 
C1: Morning stiffness >30 min 22.0% 30.8% 32.9%
C2: Improvement by movement not by rest 60.4% 72.4% 65.6%
C3: Waking up in the second half of the night because of back pain 38.9% 54.9% 46.4%
C4a: Improvement with NSAIDs within 48 h (in the whole cohort) 44.6% 57.0% 55.4%
C4b: Improvement with NSAIDs within 48 h (if taken) 73.6% 80.9% 76.4%
   NSAID,  non-steroidal  anti-inﬂ   ammatory  drug.   
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were present, the sensitivity was 85.1%, speciﬁ  city  was 
46%, LR+ 1.6, LR− 0.6 (data not shown). 
      For a diagnosis of nrSpA, ROC curve analysis showed that, if    ▶
≥1 criterion was present, the sensitivity was 81.8%, speciﬁ  c-
ity 35.9% (AUC 64.9%), LR+ 1.3, LR− 0.5. If ≥2 criteria were 
present, the sensitivity was 24.2% and the speciﬁ  city 57% 
(data not shown). 
      Thus, there were major differences between patients with AS 
and nrSpA. 
      Differences between AS and nrSpA 
  For a diagnosis of AS the following four parameters always 
proved to be relevant while this was not the case in the nrSpA 
group: 
      Improvement of back pain in motion, not at rest.    ▶
      Waking up during the second half of the night.    ▶
      Improvement with NSAIDs within 48 h.    ▶
      Alternating buttock pain.    ▶
      For the nrSpA group the following parameters were more 
relevant: 
      Age at onset ≤35 years.    ▶
      History of enthesitis.    ▶
      History of psoriasis.    ▶
      In contrast, male gender, duration of chronic back pain >30 
months, a family history of SpA, a history of uveitis, a history 
of IBD, morning stiffness >30 min (C1) did not appear to be 
relevant in any model or criteria set. 
  The quality of the models was highest for AS, followed by 
axial SpA and nrSpA.       
  DISCUSSION 
  This is the ﬁ  rst study to analyse prospectively the predictive per-
formance of clinical items for diagnosing axial SpA in a primary 
care setting. In Germany, most patients with back pain will see 
an orthopaedic surgeon as their ﬁ  rst contact with the health sys-
tem. This does not mean that GPs and physical therapists will 
not also see such patients, but these healthcare professionals 
were not included in this study. It also needs to be stressed that 
we did not only include patients who visited a physician with 
back pain for the ﬁ  rst time. 
  The results of this study show that asking single speciﬁ  c SpA-
related questions in primary care is of no value for a diagnosis 
of patients with axial SpA and that speciﬁ  c combinations are 
much more useful. Furthermore, we have identiﬁ  ed important 
differences between patients with established AS and those 
with nrSpA. 
  Our data conﬁ   rm the results of earlier studies which also 
suggested that single screening parameters are of very limited 
value and that combinations of parameters perform better.    10    It is 
important to stress that this dataset has been obtained in a pre-
speciﬁ  ed population of relatively young patients with chronic 
back pain and not in the general population. This is consistent 
with the major aim of the study, which was to develop a good 
tool to facilitate an early diagnosis of axial SpA. 
  The best likelihood ratio for a diagnosis of axial SpA calcu-
lated (excluding HLA B27) was obtained with the following ﬁ  ve 
items: age at onset ≤35 years, waking up in the second half of 
the night, alternating buttock pain, improvement by NSAIDs 
within 48 h or no NSAID and improvement by movement not 
rest. It will be necessary to test this proposal prospectively to 
further determine its usefulness. 
  Some ﬁ  ndings of this study deserve special comment. It is 
noteworthy that the age cut-off for SpA was lower in our study 
SpA (62.3%) and in 22/184 patients with other causes of back 
pain (12%). HLA B27 was not determined in 7 patients with 
SpA and 25 non-SpA patients. The prevalence of HLA B27 in the 
German population is about 9%.    17      
    Comparative performance of different items to predict SpA 
    Sensitivity, speciﬁ  city and likelihood ratios of the most 
relevant items 
  The performance of the prespeciﬁ  ed recognition criteria for the 
prediction of AS, nrSpA and axial SpA showed a sensitivity of 
70.2%, 39.4% and 52.2%, respectively, a speciﬁ  city of 74.6% 
and a quality of 72.7%, 57.3% and 63.7%, respectively.   The 
positive likelihood ratio (LR+) for axial SpA was 2.8 and the 
negative likelihood ratio (LR−) was 0.64. 
  The most useful items and their combinations are shown in 
  table 4  . This table shows that single items are of limited value 
and that the combination of any three items does not substan-
tially increase the likelihood of axial SpA.   
  While the LR+ values were all <3, the LR− of improvement by 
NSAIDs, age ≤35 years and ≥3 criteria fulﬁ  lled indicated possible 
usefulness in primary care. This was further analysed by ROC 
curve analyses (see below).   
  Regression  analyses 
  The main results of the multivariate logistic regression analysis 
are shown in   table 5  . In general, ORs were higher for AS than for 
nrSpA and there were other differences between the two (see 
below). The OR for the whole group of patients with axial SpA 
was 1.2–3.6, with different levels of signiﬁ  cance.   
  For axial SpA, the p values of the items age at onset ≤35 years, 
improvement by NSAIDs and by movement, waking up in the 
second half of the night and alternating buttock pain indicated 
a signiﬁ  cant value for identifying patients with axial SpA in pri-
mary care, while other items known to be characteristic for SpA 
were not signiﬁ  cant. For AS, the items listed for axial SpA were 
the same but, for nrSpA, different items (enthesitis and psoria-
sis) were relevant in addition to age at onset ≤35 years.   
  ROC  curve  analyses 
  The ROC curves were calculated on the basis of items with 
signiﬁ  cant results in the regression analysis for AS, early axial 
SpA and the whole group of axial SpA. An example is shown 
in   ﬁ  gure1  . 
      For a diagnosis of axial SpA, ROC curve analysis (  ﬁ  gure 1  )    ▶
showed that, if ≥4 criteria were present, the sensitivity was 
47.8%, the speciﬁ  city was 86.1% (area under curve (AUC) 
71.3%), LR+ 3.4, LR− 0.6. 
      For a diagnosis of AS, ROC curve analysis showed that, if    ▶
≥3 criteria were present, the sensitivity was 57.4%, speciﬁ  c-
ity was 85.6% (AUC 75.7%), LR+ 4.0, LR− 0.5. If ≥2 criteria 
  Table  3         Diagnoses of patients seen by the rheumatologist   
 Cohort   N   % 
Total cohort referred 322 100
Axial SpA 113 35.1
Non-radiographic axial SpA 66 20.5
 Undifferentiated  SpA 55 83.3
  SpA associated with psoriasis 5 7.6
 Reactive  SpA 3 5.0
  SpA associated with IBD 3 5.0
AS 47 14.6
Non-SpA back pain 209 64.9
      AS, ankylosing spondylitis; IBD, inﬂ  ammatory bowel disease; non-SpA, no 
spondyloarthritis; SpA, spondyloarthritis.     
14_annrheumdis151167.indd   1784 14_annrheumdis151167.indd   1784 8/31/2011   7:27:40 PM 8/31/2011   7:27:40 PMExtended report
Ann Rheum Dis 2011;70:1782–1787. doi:10.1136/ard.2011.151167 1785
psoriasis, which is a rather frequent disease. The difference 
between AS and nrSpA may be explained by observational stud-
ies suggesting that not all patients with nrSpA develop AS.    5        6    
Thus, axial SpA is not only a disease continuum from early 
(nrSpA) to advanced disease (AS), but also a covering term for 
patients who might never develop structural changes in the sac-
roiliac joints and/or the spine. This has also been suggested by 
recent studies on anti-tumour necrosis factor therapy in ‘early’    27    
and nrSpA,    28    where the mean age of the patients differed (28 
and 38 years, respectively). 
  The design and methodology used in this study ensured that 
the patients seen by the rheumatologists were representative, as 
shown in   table 1  . However, the prevalence of the prespeciﬁ  ed 
recognition items was slightly higher in the referral population, 
which may have led to more patients with SpA being seen by 
the rheumatologist (see below). The selection of the entry crite-
ria was based on published criteria for IBP and expert opinion. 
Because of the low sensitivity of the item ‘alternating buttock 
pain’, we decided to use a good response to NSAIDs as a major 
criterion because of the expected high sensitivity, and this was 
clearly conﬁ  rmed by the data obtained. We were surprised by 
the relatively bad performance of morning stiffness for >30 min 
which was only stated by about 22% of patients. The other two 
items performed as expected. As shown in   table 2  , we managed 
to include patients in the appropriate age groups, the planned 
gender ratio was met and the patient numbers planned were 
included. The majority of patients were seen within 3 weeks 
by the rheumatologists, but they appeared to have some prob-
lems with their capacity to see referral patients, which is why 
fewer than 400 patients were seen by the experts who were 
in charge of the diagnosis. These colleagues had been informed 
about the new ASAS criteria    2        3    and the established AS criteria,    13    
but we did not systematically check whether they were cor-
rectly applied. This is a possible weakness of the study, but the 
than earlier proposals for IBP.    11    This makes sense since the mean 
age at onset of AS is 26 years.    1    Currently used IBP criteria should 
be re-evaluated on this basis, having in mind that this will prob-
ably be mainly helpful in identifying patients with a high likeli-
hood of developing AS, and that this may be different in patients 
with nrSpA including those with a slowly progressive course of 
disease (see below).    6    
  On the other hand, the absence of the classic IBP criterion of 
morning stiffness was unexpected. Alternating buttock pain is 
often suggested as a possible contributor    15    since, although not 
very sensitive, this item is rather speciﬁ  c and is now shown in a 
primary care setting. However, a combination with other items 
is necessary. 
  Waking up in the second half of the night was not part of the 
original criteria set for a deﬁ  nition of IBP    11    but was introduced 
later.    23    This item is also useful in primary care, again mainly 
when combined with other items. 
  A good response to NSAIDs    24    has become increasingly estab-
lished as part of the classiﬁ  cation criteria for axial SpA,    3    as con-
ﬁ  rmed in this study. The results of a recent meta-analysis on the 
efﬁ  cacy of NSAIDs in non-speciﬁ  c low back pain    25    support this 
proposal. However, as our study also shows, not all the patients 
had taken NSAIDs. Thus, a negative answer to the question 
concerning improvement by NSAIDs may simply indicate that 
the patient had not taken the medication. This needs to be taken 
into account in future studies. Improvement by movement, 
although not really a medical intervention, is also related to a 
change in patient behaviour (moving around instead of resting). 
  Another important ﬁ  nding is that the items that perform best 
in the prediction of axial SpA differed between established AS 
and nrSpA. Both enthesitis and psoriasis were found to be use-
ful. We were surprised that enthesitis was a signiﬁ  cant item 
because, although somewhat characteristic of SpA,    26    it is not 
an easy item for patients to understand. The same is true for 
  Table  5   Odds ratios (OR)       of relevant items for a diagnosis of axial SpA: results of logistic regression analysis   
   AS    Non-radiographic axial SpA   Axial  SpA 
Age ≤35 years 2.5 (p=0.03) 2.8 (p=0.03) 2.6 (95% CI 1.5 to 4.5) (p=0.0009)
Alternating buttock pain 3.3 (p=0.005) 2.0 (p=0.1) 2.7 (95% CI 1.4 to 5.5) (p=0.003)
Improvement by NSAIDs within 48 h or no NSAID 2.9 (p=0.01) NS 1.2 (95% CI 0.7 to 2.2) (p=0.004)
Waking up in the second half of the night 3.0 (p=0.005) NS 1.9 (95% CI 1.1 to 3.2) (p=0.001)
Improvement by movement not by rest 2.0 (p=0.1) 1.9 (p=0.07) 1.9 (95% CI 1.0 to 3.4) (p=0.03)
History of psoriasis NS 3.6 (p=0.02) 2.1 (95% CI 0.7 to 6.4) (p=0.2)
History of enthesitis NS 2.7 (p=0.03) 2.3 (95% CI 1.0 to 5.1) (p=0.06)
History of anterior uveitis 7.2 (p=0.07) NS 3.6 (95% CI 0.5 to 25.3) (p=0.2)
History of arthritis 3.4 (p=0.079 2.5 (p=0.1) 2.6 (95% CI 0.9 to 7.1) (p=0.06)
Family history of SpA NS 2.5 (p=0.1) 2.3 (95% CI 0.8 to 6.6) (p=0.1)
      AS, ankylosing spondylitis; NS, not signiﬁ  cant; NSAID, non-steroidal anti-inﬂ  ammatory agent; SpA, spondyloarthritis.     
  Table  4          Sensitivity and speciﬁ  city of the main entry criteria and other SpA-speciﬁ  c items for AS and axial SpA in primary care   
 Criteria 
 Sensitivity  for 
axial SpA (AS) % 
 Speciﬁ  city for 
axial SpA (AS) % 
 Positive 
likelihood ratio 
 Negative 
likelihood ratio 
Morning stiffness >30 min 35.4 (46.8) 66.5 (68.0) 1.1 1.0
Improvement by movement not by rest 77.9 (83.0) 39.7 (36.4) 1.3 0.6
Waking up in the second half of the night because of back pain 58.4 (70.2) 57.5 (59.8) 1.7 0.7
Improvement by NSAIDs within 48 h 93.8 (78.7) 48.0 (48.3) 1.8 0.1
Alternating buttock pain 24.8 (34.0) 88.5 (88.5) 2.2 0.9
History of enthesitis 15.0 91.9 1.9 0.9
History of arthritis 10.6 95.7 2.5 0.9
Age <35 years 77.0 43.5 1.4 0.5
HLA B27 (as determined in primary care) 35.4 90.9 3.9 0.7
≥3 criteria 85.1 49.8 1.7 0.3
      AS, ankylosing spondylitis; NSAID, non-steroidal anti-inﬂ  ammatory drug; SpA, spondyloarthritis.     
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  What does this mean with regard to identifying patients 
with suspected axial SpA as early as possible? In general one 
would like to have a tool with very good sensitivity to identify 
as many patients as possible but, on the other hand, the capac-
ity to see patients may be limited and a high speciﬁ  city may 
be more important. We have presented our results in relation 
to both points of view so the rheumatologist, in cooperation 
with GPs or orthopaedic surgeons, can choose which way to 
go. Since it seems easier and more useful to stick to the criteria 
for axial SpA rather than to look at AS and nrSpA differently, 
we propose using these criteria for calculations for the selection 
process (  ﬁ  gure 1  ). Thus, in settings with very good capacity, the 
preferred strategy would be to go for 2/5 criteria with a sensitiv-
ity of 96.5% and a speciﬁ  city of 17%, which means that ﬁ  ve 
patients with chronic back pain will have to be seen to make a 
diagnosis of axial SpA in one. This strategy seems to guarantee 
that almost all patients with axial SpA can be identiﬁ  ed. In set-
tings with limited capacity the strategy could be to go for 4/5 
criteria, in which case almost every patient seen will have axial 
SpA but about half the patients will be lost. The intermediate 
strategy with 3/5 criteria has a sensitivity of 79% and a speciﬁ  c-
ity of 47%, which means that only 20% of patients with axial 
SpA would be lost and a diagnosis is likely to be made in every 
second patient. 
  It remains to be seen whether strategies including HLA B27 
testing in primary care will further improve the performance 
of the clinical parameters. This will be analysed in a separate 
paper. 
  Finally, it must be stressed that the results of this study are 
only valid in a primary care setting in Germany and therefore 
we are not discussing diagnostic or classiﬁ  cation criteria but 
rather tools that can be used to preselect patients who need to 
be seen by the rheumatologist. The proposed strategies based 
on the results of this study should be further evaluated prospec-
tively in other countries.         
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